Get started
Author

Ruchira Kumari DİSSANAYAKE

Observed names: Ruchira Dissanayake, Ruchira K Dissanayake, Ruchira K. Dissanayake
ORCID: 0000-0003-2926-7844
Observed ORCID: 0000-0003-2926-7844
OpenAlex ID: A5037539237
The presence of dehydration in paddy farmers in an area with chronic kidney disease of unknown aetiology
2019 · Indumathie Nanayakkara, Ruchira K Dissanayake, et al. · Nephrology · 22
The Effect of Bilirubin on Laboratory Investigations on Serum Creatinine: A Comparison Study Between Jaffe Reaction and Creatinase Enzymatic Method With Creatinine in Phosphate Buffered Saline Solution and Serum
2022 · Ruchira Kumari DİSSANAYAKE, Kamburawala Kankanamgee Pramodya Tharaki RANAWEERA, et al. · Clinical and Experimental Health Sciences · 9
PDF
Prevalence, knowledge and selected associated factors of anaemia among non-pregnant females of reproductive age in a tea estate community in Hantana, Kandy district, Sri Lanka.
2021 · Fathima A Sheriff, Ruchira K Dissanayake, et al. · Europe PMC (PubMed Central) · 7
Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al. · Cancer Discovery · 3
Sri Jayewardenepura Breastfeeding Study: Maternal and infant outcomes in relation to the duration of breast feeding
2010 · Pubudu De Silva, Sampath Kusumsiri, et al. · Sri Lanka Journal of Obstetrics and Gynaecology · 1
Supplementary Figure S5 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Figure S7 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Figure S6 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Figure S3 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Table S3 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Table S2 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Figure S1 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Table S1 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Note 1 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Table S4 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Figure S8 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Figure S2 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Supplementary Figure S4 from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Data from Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis
2026 · Daniel Leongamornlert, Joe Lee, et al.
Cell-state-specific mechanisms of 5-azacytidine response in myelodysplastic neoplasms
2026 · Golam Sarower Bhuyan, Feng Yan, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Works count: 20
Citation count: 42
H-index: 3
I10-index: 1
Year
Topic
Type